Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The form states that Panmure Gordon made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares on August 31, 2023. The highest price per unit paid for the purchases was 0.02725, while the lowest price per unit paid was 0.0262. The sales were made at a price of 0.0288 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. The form also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities. The contact person for this disclosure is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.